ES2528055T3 - Composición farmacéutica que comprende 3-beta-hidroxi-17-(1-H-bencimidazol-1-il)androsta-5,16-dieno - Google Patents

Composición farmacéutica que comprende 3-beta-hidroxi-17-(1-H-bencimidazol-1-il)androsta-5,16-dieno Download PDF

Info

Publication number
ES2528055T3
ES2528055T3 ES10150763.0T ES10150763T ES2528055T3 ES 2528055 T3 ES2528055 T3 ES 2528055T3 ES 10150763 T ES10150763 T ES 10150763T ES 2528055 T3 ES2528055 T3 ES 2528055T3
Authority
ES
Spain
Prior art keywords
compound
diene
compounds
androsta
benzimidazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES10150763.0T
Other languages
English (en)
Spanish (es)
Inventor
Angela Brodie
Vincent Njar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Maryland Baltimore
University of Maryland College Park
Original Assignee
University of Maryland Baltimore
University of Maryland College Park
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Maryland Baltimore, University of Maryland College Park filed Critical University of Maryland Baltimore
Application granted granted Critical
Publication of ES2528055T3 publication Critical patent/ES2528055T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES10150763.0T 2005-03-02 2006-03-02 Composición farmacéutica que comprende 3-beta-hidroxi-17-(1-H-bencimidazol-1-il)androsta-5,16-dieno Expired - Lifetime ES2528055T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65739005P 2005-03-02 2005-03-02
US657390P 2005-03-02

Publications (1)

Publication Number Publication Date
ES2528055T3 true ES2528055T3 (es) 2015-02-03

Family

ID=36941503

Family Applications (2)

Application Number Title Priority Date Filing Date
ES10150763.0T Expired - Lifetime ES2528055T3 (es) 2005-03-02 2006-03-02 Composición farmacéutica que comprende 3-beta-hidroxi-17-(1-H-bencimidazol-1-il)androsta-5,16-dieno
ES06736460T Expired - Lifetime ES2353413T3 (es) 2005-03-02 2006-03-02 3-beta-hidroxi-17-(1h-bencimidazol-1-il)androsta-5,16-dieno para uso en el tratamiento de una enfermedad de la próstata.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES06736460T Expired - Lifetime ES2353413T3 (es) 2005-03-02 2006-03-02 3-beta-hidroxi-17-(1h-bencimidazol-1-il)androsta-5,16-dieno para uso en el tratamiento de una enfermedad de la próstata.

Country Status (21)

Country Link
US (1) US7875599B2 (https=)
EP (2) EP2206719B1 (https=)
JP (2) JP5130453B2 (https=)
KR (1) KR101380959B1 (https=)
CN (2) CN103349664A (https=)
AT (1) ATE482969T1 (https=)
AU (1) AU2006218711B2 (https=)
BR (1) BRPI0607523A2 (https=)
CA (1) CA2599953C (https=)
DE (1) DE602006017175D1 (https=)
DK (2) DK1853619T3 (https=)
EA (1) EA019560B1 (https=)
ES (2) ES2528055T3 (https=)
IL (3) IL185608A (https=)
MX (1) MX2007010593A (https=)
NZ (1) NZ561571A (https=)
PL (2) PL1853619T3 (https=)
PT (2) PT2206719E (https=)
SI (2) SI1853619T1 (https=)
WO (1) WO2006093993A1 (https=)
ZA (1) ZA200708106B (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8569275B2 (en) 2002-08-28 2013-10-29 Harbor Therapeutics, Inc. Steroids having 7-oxgen and 17-heteroaryl substitution
US7875599B2 (en) * 2005-03-02 2011-01-25 University Of Maryland C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens, in vitro biological activities, pharmacokinetics and antitumor activity
EP2167090A4 (en) 2007-06-06 2010-08-25 Univ Maryland HDAC INHIBITORS AND HORMONE TREATMENT MEDICAMENTS
GB2470873A (en) * 2008-03-12 2010-12-08 Univ Maryland Androgen receptor inactivation contributes to antitumor efficacy of CYP17 inhibitors in prostrate cancer
US20100048524A1 (en) * 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
GB2470700B (en) * 2008-03-25 2012-08-08 Univ Maryland C-17 heteroaryl steroidal CYP17 inhibitors
US8785423B2 (en) * 2008-04-14 2014-07-22 University Of Maryland, Baltimore Compositions and methods of inducing endoplasmic reticulum stress response for the treatment of cell proliferative diseases
EP2334686B1 (en) 2008-08-28 2019-02-27 President and Fellows of Harvard College Cortistatin analogues and syntheses therof
EP2362872A4 (en) * 2008-10-28 2012-05-30 Biomarin Pharm Inc DECAHYDRO-1H-INDENOCHINOLINONE AND DECAHYDRO-3H-CYCLOPENTAPHENANTHRIDINONE CYP17 HEMMER
GB2479337A (en) * 2009-02-05 2011-10-05 Tokai Pharmaceuticals Inc Combination of a 17 alpha-hydroxylase/c17, 20-lyase inhibitor with an additional therapeutic agent
WO2010091306A1 (en) 2009-02-05 2010-08-12 Tokai Pharmaceuticals Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
WO2010091303A1 (en) * 2009-02-05 2010-08-12 Tokai Pharmaceuticals Novel steroidal cyp17 inhibitors/antiandrogens
UY32730A (es) 2009-06-26 2011-01-31 Novartis Ag Inhibidores de cyp17
WO2011017534A2 (en) 2009-08-07 2011-02-10 Tokai Pharmaceuticals, Inc. Treatment of prostate cancer
EP2499151A4 (en) * 2009-11-13 2013-03-20 Tokai Pharmaceuticals Inc MAMMALIAN STEROID METABOLITES
EP2506855A4 (en) * 2009-11-30 2014-07-30 Harbor Biosciences Inc ANTICARCINOMA COMPOUNDS AND SCREENING METHODS
US8946260B2 (en) 2010-09-16 2015-02-03 Novartis Ag 17α-hydroxylase/C17,20-lyase inhibitors
AU2011343637A1 (en) * 2010-12-16 2013-05-30 Biomarin Pharmaceutical Inc. C- 17 -heteroaryl steroidal compounds as inhibitors of CYP11B, CYP17, and/or CYP21
AU2012249421B9 (en) 2011-04-28 2015-10-22 Novartis Ag 17alpha-hydroxylase/C17,20-lyase inhibitors
BR112014001440A2 (pt) * 2011-07-18 2017-02-21 Tokai Pharmaceuticals Inc novas composições e métodos para o tratamento de câncer de próstata
AU2012358219A1 (en) * 2011-12-22 2014-07-10 Tokai Pharmaceuticals, Inc. Methods and compositions for combination therapy using P13K/mTOR inhibitors
KR20150127720A (ko) 2013-03-14 2015-11-17 유니버시티 오브 매릴랜드, 발티모어 안드로겐 수용체 하향 조절제 및 그의 용도
US9694005B2 (en) 2013-04-04 2017-07-04 University Of Maryland, Baltimore Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity
CA2920317A1 (en) 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
SG11201605178WA (en) 2013-12-24 2016-07-28 Harvard College Cortistatin analogues and syntheses and uses thereof
CN103694299A (zh) * 2014-01-13 2014-04-02 中国药科大学 甾体类雄激素受体抑制剂、其制备方法及其医药用途
WO2016119742A1 (zh) * 2015-01-29 2016-08-04 苏州晶云药物科技有限公司 (3β)-17-(1H-苯并咪唑-1-基)雄甾-5，16-二烯-3-醇的盐及其制备方法
WO2016182932A1 (en) 2015-05-08 2016-11-17 President And Fellows Of Harvard College Cortistatin analogues, syntheses, and uses thereof
WO2017004411A1 (en) 2015-07-01 2017-01-05 President And Fellows Of Harvard College Cortistatin analogues and syntheses and uses thereof
US10682362B2 (en) 2015-10-14 2020-06-16 Wayne State University Treatments and diagnostics for cancers
IT201600083406A1 (it) * 2016-08-08 2018-02-08 Ind Chimica Srl PROCESSO PER LA PREPARAZIONE DI 3β-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE
IT201600121375A1 (it) * 2016-11-30 2018-05-30 Ind Chimica Srl PROCESSO PER LA PREPARAZIONE DI 3ß-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE
US11390645B2 (en) 2016-08-08 2022-07-19 Industriale Chimica S.R.L. Process for the preparation of 3β-hydroxy-17-(1H-benzimidazol-1-YL) androsta-5,16-diene
CA3087286C (en) 2018-02-13 2023-06-27 Dana-Farber Cancer Institute, Inc. Cyclin-dependent kinase degraders and methods of use
US20200369715A1 (en) * 2018-02-13 2020-11-26 Dana-Farber Cancer Institute, Inc. Cyclin-dependent kinase inhibitors and methods of use
US12410194B2 (en) 2019-11-26 2025-09-09 Dana-Farber Cancer Institute, Inc. Potent and selective azaindole inhibitors of CDK8 and CDK19

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA27440A (en) 1887-08-16 James T. Walsh Art of making sheet metal cans, for packing meats, fruits, vegetables, etc.
CH621803A5 (https=) * 1974-08-08 1981-02-27 Siphar Sa
US5604213A (en) * 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
US5994335A (en) * 1997-10-17 1999-11-30 The University Of Maryland, Baltimore 17-azolyl steroids useful as androgen synthesis inhibitors
JP4855253B2 (ja) 2003-07-29 2012-01-18 ドムペ・ファ．ル．マ・ソチエタ・ペル・アツィオーニ 幹細胞動員に有用な医薬の組み合わせ
US7875599B2 (en) * 2005-03-02 2011-01-25 University Of Maryland C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens, in vitro biological activities, pharmacokinetics and antitumor activity

Also Published As

Publication number Publication date
EP2206719B1 (en) 2014-10-22
DK1853619T3 (da) 2011-01-10
KR20070120119A (ko) 2007-12-21
SI2206719T1 (sl) 2015-03-31
AU2006218711A2 (en) 2006-09-08
IL210478A0 (en) 2011-03-31
JP5130453B2 (ja) 2013-01-30
MX2007010593A (es) 2008-02-20
PT1853619E (pt) 2011-01-03
CA2599953A1 (en) 2006-09-08
WO2006093993A1 (en) 2006-09-08
EP1853619A4 (en) 2009-08-26
JP2012255026A (ja) 2012-12-27
DE602006017175D1 (de) 2010-11-11
IL210480A0 (en) 2011-03-31
EP1853619A1 (en) 2007-11-14
JP5613206B2 (ja) 2014-10-22
PT2206719E (pt) 2015-02-05
NZ561571A (en) 2009-09-25
EA200701872A1 (ru) 2008-06-30
ZA200708106B (en) 2008-12-31
AU2006218711B2 (en) 2010-11-11
AU2006218711A1 (en) 2006-09-08
BRPI0607523A2 (pt) 2009-09-08
PL1853619T3 (pl) 2011-03-31
IL210480A (en) 2015-06-30
US20080280864A1 (en) 2008-11-13
PL2206719T3 (pl) 2015-03-31
CN103349664A (zh) 2013-10-16
KR101380959B1 (ko) 2014-04-04
CA2599953C (en) 2013-08-13
DK2206719T3 (en) 2015-01-26
SI1853619T1 (sl) 2011-01-31
JP2008536807A (ja) 2008-09-11
CN101155823A (zh) 2008-04-02
IL185608A (en) 2016-06-30
IL185608A0 (en) 2008-01-06
EA019560B1 (ru) 2014-04-30
US7875599B2 (en) 2011-01-25
ATE482969T1 (de) 2010-10-15
EP2206719A3 (en) 2011-01-05
EP2206719A2 (en) 2010-07-14
HK1115387A1 (en) 2008-11-28
EP1853619B1 (en) 2010-09-29
ES2353413T3 (es) 2011-03-01

Similar Documents

Publication Publication Date Title
ES2528055T3 (es) Composición farmacéutica que comprende 3-beta-hidroxi-17-(1-H-bencimidazol-1-il)androsta-5,16-dieno
US10098896B2 (en) C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens, in vitro biological activities, pharmacokinetics and antitumor activity
Bruno et al. Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model
ES2552087T3 (es) Nuevos profármacos de inhibidores de CYP17 esteroidales/antiandrógenos
US9295679B2 (en) Prodrugs of C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
ES2290984T3 (es) Inhibidores de la sintesis de androgenos.
US6200965B1 (en) 17-Azolyl steroids useful as androgren synthesis inhibitors
HK1115387B (en) 3-beta-hydroxy-17-(1h-benzimidazol-1-yl)androsta-5,16-diene for use in the treatment of a prostate disease